Scholarlink

Introduction <p>Glucagon-like peptide-1 (GLP-1) agonist and combined GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist use has dramatically increased in recent years. While their side effect profile is often manageable, they can lead to serious complications.</p> Case Presentation <p>We present a case of colonic ischemia in a young patient who experienced significant nausea, vomiting, and abdominal pain after initiation of semaglutide. Imaging was unremarkable, but after an episode of hematochezia, a colonoscopy was performed, which grossly showed signs of colonic ischemia with biopsied tissue demonstrating changes consistent with ischemic mucosa. A comprehensive hematology, cardiology, and gastrointestinal workup was performed, which did not elucidate a cause for the colonic ischemia. The likely cause was deemed to be hypovolemia resulting from the recent initiation of semaglutide.</p> Conclusions <p>Following the initiation of semaglutide, other GLP-1 agonists, or GLP-1/GIP dual agonists, practitioners should be aware of the potential severe complications, such as colonic ischemia, and properly educate their patients about these risks.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Colonic Ischemia Following Semaglutide Use: A Case Report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月17日

查看全文
  • Luke Kosel,
  • Mckenzie Burian,
  • Sydney Rooney,
  • Saurabhkumar Limani

摘要

Introduction

Glucagon-like peptide-1 (GLP-1) agonist and combined GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) agonist use has dramatically increased in recent years. While their side effect profile is often manageable, they can lead to serious complications.

Case Presentation

We present a case of colonic ischemia in a young patient who experienced significant nausea, vomiting, and abdominal pain after initiation of semaglutide. Imaging was unremarkable, but after an episode of hematochezia, a colonoscopy was performed, which grossly showed signs of colonic ischemia with biopsied tissue demonstrating changes consistent with ischemic mucosa. A comprehensive hematology, cardiology, and gastrointestinal workup was performed, which did not elucidate a cause for the colonic ischemia. The likely cause was deemed to be hypovolemia resulting from the recent initiation of semaglutide.

Conclusions

Following the initiation of semaglutide, other GLP-1 agonists, or GLP-1/GIP dual agonists, practitioners should be aware of the potential severe complications, such as colonic ischemia, and properly educate their patients about these risks.